Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Münster, Münster, Germany.
Institute of Immunology, University Hospital Münster, Münster, Germany.
Dis Markers. 2018 May 28;2018:2040746. doi: 10.1155/2018/2040746. eCollection 2018.
Peritonsillar inflammation is a common characteristic of both peritonsillar abscess (PTA) and peritonsillitis (PC). The aim of the present study was to apply the PTA score as an objective criterion to identify patients with peritonsillar inflammation (PI) who might profit from medical treatment. Hence, the recently developed PTA score was applied retrospectively on patients suffering from acute tonsillitis, peritonsillitis, and peritonsillar abscess. Analysis of the clinical data, the follow-up, and the initial PTA score was performed. Patients with peritonsillar inflammation show significant higher PTA score values compared to patients with acute tonsillitis without peritonsillar inflammation and healthy controls. Patients with a PTA score ≤ 2 profited from medical treatment consisting of antibiotics in 92.3% of the cases. In 89.2% of the patients with a PTA score > 2, pus was detected during abscess relief. Patients with peritonsillar inflammation who profited from medical treatment had significantly reduced PTA score values and a reduced duration of hospitalization compared to the patients with abscess relief. Thus, the PTA score has the potential as an objective criterion to identify patients with peritonsillar inflammation profiting from medical treatment. Hence, application of the PTA score helps to determine an optimal, individualized treatment approach and might reduce utilization of medical resources.
扁桃体周炎症是扁桃体周脓肿（PTA）和扁桃体周炎（PC）的共同特征。本研究旨在应用 PTA 评分作为一种客观标准，来确定可能从药物治疗中获益的扁桃体周炎症（PI）患者。因此，本研究回顾性地应用最近开发的 PTA 评分对患有急性扁桃体炎、扁桃体周炎和扁桃体周脓肿的患者进行评估。分析了临床数据、随访情况和初始 PTA 评分。与无扁桃体周炎症的急性扁桃体炎患者和健康对照组相比，患有扁桃体周炎症的患者 PTA 评分值显著更高。PTA 评分值≤2 的患者中，92.3%的患者受益于抗生素治疗。PTA 评分值>2 的患者中，89.2%的患者在脓肿缓解时发现有脓液。与脓肿缓解的患者相比，从药物治疗中获益的扁桃体周炎症患者的 PTA 评分值和住院时间明显减少。因此，PTA 评分具有作为一种客观标准来识别可能从药物治疗中获益的扁桃体周炎症患者的潜力。因此，应用 PTA 评分有助于确定最佳的个体化治疗方法，并可能减少医疗资源的利用。
